Title: Differential response to abiraterone acetate and di-n-butyl phthalate in an androgen-sensitive human fetal testis xenograft bioassay.
Journal: Toxicological sciences : an official journal of the Society of Toxicology20140301
Title: Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).
Journal: BMC urology20140101
Title: Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC).
Journal: BJU international20120801
Title: Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer.
Journal: Cancer chemotherapy and pharmacology20120801
Title: Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20120701
Title: Discovery of potent and orally bioavailable 17β-hydroxysteroid dehydrogenase type 3 inhibitors.
Journal: Bioorganic & medicinal chemistry20120515
Title: Novel molecular targets for the therapy of castration-resistant prostate cancer.
Journal: European urology20120501
Title: Beyond castration-defining future directions in the hormonal treatment of prostate cancer.
Journal: Hormones & cancer20120401
Title: Abiraterone acetate: redefining hormone treatment for advanced prostate cancer.
Journal: Drug discovery today20120301
Title: Advances in the management of high-risk localised and metastatic prostate cancer.
Journal: BJU international20120301
Title: Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer.
Journal: Drugs & aging20120301
Title: The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer.
Journal: Journal of investigative medicine : the official publication of the American Federation for Clinical Research20120201
Title: Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor.
Journal: Clinical pharmacology and therapeutics20120101
Title: Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.
Journal: Expert review of anticancer therapy20120101
Title: Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
Journal: Drug design, development and therapy20120101
Title: Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches.
Journal: Oncology (Williston Park, N.Y.)20120101
Title: Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling.
Journal: Case reports in oncology20120101
Title: Drugs in traffic: the road to approval.
Journal: Nature medicine20111206
Title: TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
Journal: European urology20111101
Title: Circulating tumour cells as surrogate biomarkers in castration-resistant prostate cancer trials.
Journal: European urology20111101
Title: Clinical implications of the 5α-androstanedione pathway for castration-resistant prostate cancer.
Journal: Future oncology (London, England)20111101
Title: Abiraterone acetate: in metastatic castration-resistant prostate cancer.
Journal: Drugs20111022
Title: Flushing oral oncology drugs down the toilet.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology20111020
Title: Abiraterone acetate for prostate cancer: a new era of hormonal therapies.
Journal: Asian journal of andrology20110901
Title: Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20110715
Title: [The trend toward development of novel agents based on the mechanism of prostate cancer progression].
Journal: Nihon rinsho. Japanese journal of clinical medicine20110601
Title: CYP17 inhibitors for prostate cancer therapy.
Journal: The Journal of steroid biochemistry and molecular biology20110501
Title: Roflumilast, indacaterol maleate, and abiraterone acetate.
Journal: Journal of the American Pharmacists Association : JAPhA20110101
Title: Abiraterone acetate.
Journal: Drugs in R&D20101101
Title: CYP17 inhibition as a hormonal strategy for prostate cancer.
Journal: Nature clinical practice. Urology20081101
Title: Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.
Journal: Bioorganic & medicinal chemistry20080815
Title: Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure.
Journal: Bioorganic & medicinal chemistry20080215
Title: Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer.
Journal: British journal of cancer20040614
Title: Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer.
Journal: Journal of medicinal chemistry19950623
Title: Stein MN, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl. 2014 May-Jun;16(3):387-400.
Title: Richards J, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012 May 1;72(9):2176-82.
Title: Li R, et al. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res. 2012 Jul 1;18(13):3571-9.
Title: Lee GT, et al. Intracrine androgen biosynthesis in renal cell carcinoma. Br J Cancer. 2017 Mar 28;116(7):937-943.
Title: A O'Donnell, et al. Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. British Journal of Cancervolume 90, pages2317–2325 (2004)
